Pathological effects and mode of action of antilymphocyte serum treatment.
D000818:Animals; D000831:Animals, Newborn; D000893:Anti-Inflammatory Agents; D000937:Antigen-Antibody Reactions; D000961:Antilymphocyte Serum / Q000009:adverse effects / Q000494:pharmacology*; D001183:Arthus Reaction / Q000517:prevention & control; D001485:Basement Membrane / Q000276:immunology; D002462:Cell Membrane / Q000276:immunology; D003165:Complement System Proteins; D003348:Cortisone / Q000494:pharmacology; D003520:Cyclophosphamide / Q000494:pharmacology; D003877:Dermatitis, Contact / Q000517:prevention & control; D004336:Drug Antagonism; D004357:Drug Synergism; D006168:Guinea Pigs; D006644:Histiocytes; D006648:Histocompatibility; D007108:Immune Tolerance; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D007668:Kidney / Q000473:pathology; D007678:Kidney Glomerulus / Q000276:immunology; D007684:Kidney Tubules / Q000276:immunology; D008198:Lymph Nodes / Q000166:cytology / Q000276:immunology / Q000473:pathology; D008214:Lymphocytes / Q000276:immunology; D011239:Prednisolone / Q000494:pharmacology; D012882:Skin Tests; D013934:Thymectomy; D013950:Thymus Gland / Q000276:immunology
D000893:Anti-Inflammatory Agents; D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D003165:Complement System Proteins; D011239:Prednisolone; D003348:Cortisone